Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives
Carlo Lavalle, Sara Trivigno, Giampaolo Vetta, Michele Magnocavallo, Marco Valerio Mariani, Luca Santini, Giovanni B. Forleo, Massimo Grimaldi, Roberto Badagliacca, Luigi Lanata, Renato Pietro Ricci
Abstract
Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance in AF and the treatment of idiopathic ventricular arrhythmias (IVA) in absence of ischaemic and structural heart disease on the basis of CAST data. Recent studies enrolling patients with different structural heart diseases demonstrated good effectiveness and safety profile of flecainide. The purpose of this review is to assess current evidence for appropriate and safe use of flecainide, 30 years after CAST data, in the light of new diagnostic and therapeutic tools in the field of ischaemic and non-ischaemic heart disease.